HOME >> BIOLOGY >> NEWS
UGA study reveals a new way of looking at vaccine development

University of Georgia researchers have given vaccine developers a new tool that could lead to the development of designer vaccines that protect against a wider range of diseases or work against diseases that are currently hard to prevent.

In a study published in the May 23 edition of the journal Proceedings of the National Academy of Sciences, Robert J. Woods and his colleagues demonstrate precisely how antibodies react differently to two common disease-causing bacteria Group B Streptococcus and Streptococcus pneumoniae.

Their 3D modeling technique gives researchers the power to effectively see how the body's antibodies bind to the chains of sugars on the outer coats of bacteria. In cases where antibodies don't bind to the sugars and no immune response is triggered, researchers could chemically alter the sugars so that body recognizes the bacteria as a threat and mounts a defense.

"What you'd really like is to control either the broadness of the immune response so that you can take one vaccine and protect against multiple strains of the bacteria," said Woods, lead author of the study and associate professor of biochemistry at the UGA Complex Carbohydrate Research Center. "Or you could take a strain that's not easy to vaccinate against and induce an immune response using a synthetically modified sugar."

Woods and his colleagues chose to examine Group B Streptococcus and Streptococcus pneumoniae because of their virulence and because they have very similar outer coats. Chemically, strains III and 14 of these two bacteria share a common molecular backbone. The only difference is a missing acidic sugar in the side chain of Streptococcus pneumoniae 14.

The immune system can generate antibodies against both bacteria but despite the similarities in their surface sugars antibodies against the one bacterium do not generally recognize the other and so do not protect against infection by the other.

To understand this lack of
'"/>

Contact: Kim Osborne
kcarlyle@uga.edu
706-542-8083
University of Georgia
22-May-2006


Page: 1 2 3

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Clones on task serve greater good, evolutionary study shows
3. Pollution causes 40 percent of deaths worldwide, study finds
4. A study by the MUHC and McGill University opens a new door to understanding cancer
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Preclinical study links gene to brain aneurysm formation
7. In limiting life span, study finds booming bacteria innocent
8. Multicenter study nets new lung tumor-suppressor gene
9. MIT study: Maturity brings richer memories
10. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study
11. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2019)... ... January 03, 2019 , ... Over the ... into their drug discovery research workflows with biology ranging from single cell-type spheroids ... of in vitro studies, they create several challenges that need to be overcome ...
(Date:12/27/2018)... FRANCISCO (PRWEB) , ... December 27, 2018 , ... ... annual Microbiome Conference at JPM as part of the JP Morgan 37th Annual ... innovative scientists and physicians, and members of the investment community. , Since ...
(Date:12/20/2018)... ... December 20, 2018 , ... Human Factors and product ... a new usability/observation room. This addition will help meet the increased industry demand ... delivery devices/combination products are safe and easy to use when released to the ...
Breaking Biology News(10 mins):
(Date:1/10/2019)... Fla. (PRWEB) , ... January ... ... Geometrical Implant Co, (SAGICO), an innovative spinal implant company, announced today that ... in San Francisco, California. The annual J.P. Morgan Healthcare Conference is ...
(Date:1/7/2019)... SEONGNAM, South Korea (PRWEB) , ... January 07, ... ... has completed Phase 1 clinical trials of its Parkinson's Disease drug candidate, code-named ... disease-modifying treatment of Parkinson's Disease. The trial took place in South Korea. ...
(Date:1/4/2019)... ... January 03, 2019 , ... Calidi Biotherapeutics, Inc., ... today announced the founding of a scientific and medical advisory board (SMAB). The ... leaders in the Immuno-Oncology field. The founding members of Calidi Biotherapeutics SMAB include ...
(Date:12/18/2018)... ... December 17, 2018 , ... ABCT ... emerging biosciences ventures invited to participate in the annual program. Twelve ventures will ... plans and a professional network. All startups receive an entrepreneur coach, access to ...
Breaking Biology Technology:
Cached News: